Lipocine Inc. Files 8-K for Corporate Updates
Ticker: LPCN · Form: 8-K · Filed: Nov 5, 2024 · CIK: 1535955
| Field | Detail |
|---|---|
| Company | Lipocine Inc. (LPCN) |
| Form Type | 8-K |
| Filed Date | Nov 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, sec-filing, 8-k
Related Tickers: LPCN
TL;DR
Lipocine Inc. (LPCN) filed an 8-K on Nov 5, 2024, for corporate events. No specific details yet.
AI Summary
Lipocine Inc. filed an 8-K on November 5, 2024, reporting other events and financial statements. The company, incorporated in Delaware with its principal executive offices in Salt Lake City, Utah, previously operated under the name Marathon Bar Corp until November 30, 2011. The filing does not detail specific transactions or financial figures but serves as a notification of corporate events.
Why It Matters
This filing indicates Lipocine Inc. is making official disclosures to the SEC regarding its corporate activities, which could include significant business developments or financial reporting.
Risk Assessment
Risk Level: low — The filing is a standard corporate disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- Lipocine Inc. (company) — Registrant
- Marathon Bar Corp (company) — Former company name
- November 5, 2024 (date) — Date of report
- November 30, 2011 (date) — Date of name change
- Delaware (jurisdiction) — State of incorporation
- Salt Lake City, Utah (location) — Principal executive offices
FAQ
What specific 'Other Events' are being reported by Lipocine Inc. in this 8-K filing?
The provided text of the 8-K filing does not specify the details of the 'Other Events' beyond listing it as an item of information.
What is the significance of the 'Financial Statements and Exhibits' being listed as an item of information?
This indicates that the filing includes or references financial statements and other exhibits, which are typically part of regular SEC reporting or specific corporate actions.
When did Lipocine Inc. change its name from Marathon Bar Corp?
Lipocine Inc. changed its name from Marathon Bar Corp on November 30, 2011.
Where are Lipocine Inc.'s principal executive offices located?
Lipocine Inc.'s principal executive offices are located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah.
What is the SEC file number for Lipocine Inc.?
The SEC file number for Lipocine Inc. is 001-36357.
Filing Stats: 456 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-11-05 16:37:36
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 2KB
- form8-k_001.jpg (GRAPHIC) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 1500KB
- 0001493152-24-043670.txt ( ) — 2315KB
- lpcn-20241105.xsd (EX-101.SCH) — 3KB
- lpcn-20241105_lab.xml (EX-101.LAB) — 33KB
- lpcn-20241105_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events On Tuesday November 5, 2024, key opinion leader Dr. Frank Greenway presented a poster entitled "Oral LPCN 2401 Reduces Fat Mass and Increases Lean Mass in Men with Obesity" at the Obesity Society's Annual Obesity Week conference in San Antonio, Texas. The poster is presented as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed with this report: Exhibit No. Description 99.1 Poster presentation entitled "Oral LPCN 2401 Reduces Fat Mass and Increases Lean Mass in Men with Obesity" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: November 5, 2024 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer